41 results about "Hyperfunction" patented technology

The invention provides a traditional Chinese medicine contrast medium adjuvant used for B ultrasonic, which comprises the following materials in part by weight: 10-20 parts of bighead atractylodes rhizome, 10-20 parts of poria cocos, 10-20 parts of turmeric, 10-20 parts of tangerine peel, 10-20 parts of cortex magnoliae officinalis, 10-20 parts of radix aucklandiae, 10-20 parts of Rhizoma atractylodis, 10-20 parts of cuttlebone, 10-20 parts of calcined oyster shell, 10-20 parts of Chinese yam, 10-20 parts of charred triplet, 10-20 parts of myristica fragrans, 10-20 parts of gizzard pepsin, 10-20 parts of rhizome cyperi, 10-20 parts of codonopsis pilosula, 10-20 parts of combined spicebush root, 10-20 parts of eclipta, 10-20 parts of jasmine, 10-20 parts of baical skullcap root and 10-20 parts of field pennycress. The traditional Chinese medicine contrast medium adjuvant used for B ultrasonic provided by the invention not only can adapt to stomach hyperfunction type, but also can adapt to decreased stomach function type, and also can be applied to the mixed type of various flatulence and mucinosis, check time is short, imaging rate is high, and preparation process is simple and practical. The contrast medium adjuvant has no obvious toxic side effect and has prospect on further development research.

Chinese traditional medicine for treating exophthalmic goiter in combination with diarrhea, wherein the recipe includes root of herbaceous peony 10g, nutgrass flatsedge rhizome 10g, white atractylodes rhizome 12g, coptis root 6g, root of pilose asiabell 15g, poria cocos wolf 10g, dried orange peel 6g, white hyacinth bean 10g, amomum fruit 3g, licorice root 6g, plantain seeds 20g, kudzuvine root 10g, banksia rose 10g, crude malt 15g, baked malt 15g, prunella spike 10g, thunberg fritillary bulb 15g, baikal skullcap root 8g, gentian root 12g, pericarpium trichosanthis 20g, grassleaved sweetflag rhizome 8g, schisandra fruit 10g, aspongopus 6g, spikenard 8g, magnolia bark 12g, tuber fleeceflower stem 9g and euphoria longan steud 15g. The Chinese medicament has simplified recipe, easy preparing process and low price.

Novel compounds which are inhibitors of receptor tyrosine kinases of the AXL receptor family are described herein. These compounds are suitable for the treatment or prevention of disorders associated with, accompanied by or caused by hyperfunction of a receptor of the AXL family. The compounds are suitable for the treatment of hyperproliferative disorders, such as cancer, particularly cancer metastases.

The invention relates to a medicinal preparation for treating thyroid gland hyperfunction and process for its preparation, wherein raw materials include (by weight proportion) rough gentian, seabuckthorn fruit, selfheal and cape jasmine.

The invention discloses a pharmaceutical composition for the treatment of depression prepared by raw materials of paeoniflorin and albiflorin. The invention also discloses a preparation method of the pharmaceutical composition. The experiments prove that the pharmaceutical composition of the invention can obviously reduce the suspension tail immovability time of the mouse to be tested, from which the antidepressant function of the composition in the experiment can be inferred; the pharmaceutical composition of the invention can obviously withstand the temperature reduction of the mouse caused by the reserpine, from which the relevance of the antidepressan mechanism of the composition and the regulation of the monoamine transmitters can be inferred; and the pharmaceutical composition of the invention can significantly reduce the amounts of horizontal movement and vertical movement of the model rat, reduce the electric shock times in the training period and testing period of step down passive avoidance test, significantly reduce the CRH secretion of hypothalamus and ACTH secretion of hypophysis, and significantly reduce the CORT content in the blood, from which the antidepressant function of the pharmaceutical composition and one of the mechanisms of excessive hyperfunction suppression of HPA axis can be inferred.

The invention provides method of diagnosing a receptor tyrosine kinase (RTK)-hyperfunction-induced disorder or a genetic predisposition therefor in a mammal. The method comprises determining the presence of a nucleic acid encoding a mutated fibroblast growth factor receptor-4 (FGFR-4) protein in a nucleic acid sample from a mammal. The presence of a nucleic acid encoding a mutated FGFR-4 protein is indicative of an RTK-hyperfunction-induced disorder or a genetic predisposition therefor.

A Chinese herba preparation for recuperating and curing ovarian hypoplasia of young girls or adult women is hot drink particles or a tea bag or a granular preparation consisting of kudzu roots, hawthorn, soya beans, red beans, black beans, fructus ligustri lucidi, eclipta alba, honeysuckle, Chinese rose, raw liquorice, dried tangerine or orange peels, fructus amomi, folium ginseng, dipsacus roots, eucommia bark, mistletoe, Japanese raspberry roots, winged euonymus twig, radix trichosanthis, pearl powder, yam flour, medicine beans and a packaging material. The Chinese herba preparation is used for preventing, recuperating and curing diseases including ovarian dysplasia or retardation of the young girls, ovarian hypofunction or hyperfunction, too little or too much estrogen secretion and ovarian and uterus dysgenesis of young married women, premature ovarian failure of older women, and barrenness of fertile women due to hypoplasia of ovum of ovarian, is used for moistening skin, retaining youthful looks and eliminating macula, and has the advantages that total effective rate of clinical recuperating and curing reaches 100% and the like.

The invention relates to an urea compound of the structure shown in a general formula I, a preparation method thereof, a drug composition containing the urea compound and an application of the drug composition in preparation of drugs used for treating inflammatory reaction, immunity hyperfunction and organ transplantation. R1-R7, X, Y and n in the general formula I disclosed in the invention are defined in the specification and claims.

The invention belongs to the technical field of biological medicine and particularly relates to an immunosuppressive cell preparation as well as a preparation method and an application thereof. The invention provides the immunosuppressive cell preparation and the application of the immunosuppressive cell preparation in preparation of SLE (systemic lupus erythematosus) preventing and treating drugs and further provides the preparation method of the immunosuppressive cell preparation. The immunosuppressive cell preparation comprises Treg cells, umbilical cord mesenchymal stem cell exosomes, cord blood mononuclear cells, umbilical cord blood plasma and a medically acceptable solvent. The immunosuppressive cell preparation has the beneficial effects as follows: the Treg cells and the umbilical cord mesenchymal stem cell exosomes play a role in inhibiting body immunity hyperfunction and balancing body immune system function firstly, the cord blood mononuclear cells play a role in immunoregulation, blood environment is improved, and the problem of immune system disorder is solved fundamentally.

The invention provides an injection of a serine protease inhibitor. The injection contains 0.05mg/ml to 30mg/ml of the serine protease inhibitor recombinant textilinin-1, a pH buffering agent, a surfactant, polyalcohol, amino acid and a bacteriostatic agent. The injection of the serine protease inhibitor has the advantages that the stability of protein medicine is improved; the preparation process is simple; the fibrinolysis-resistant treatment effect is good; and the injection can be used for treating and preventing fibrinolysis hyperfunction hemorrhage and blood loss caused by various reasons in clinics.

The invention discloses a technical formula and a preparation method of a tranexamic acid freeze-dried powder injection. The tranexamic acid freeze-dried powder injection comprises tranexamic acid; a mixed solvent comprising 5-30% of tertbutyl alcohol and the balance of injection water in percentage by volume is used in the preparation process, and the concentration of tranexamic acid in the mixed solvent is 30-150 mg/ml. The preparation process comprises the following steps: measuring tertbutyl alcohol, adding injection water, mixing uniformly, cooling to 2-10 DEG C, keeping the temperature, adding tranexamic acid, stirring to enable tranexamic acid to be dissolved, filtering, filling, adding plugs, placing the mixture into discs, freeze-drying, pressing the plugs, unboxing, sealing opening through a cover, and packaging after passing the quality inspection to obtain the tranexamic acid freeze-dried powder injection. The tranexamic acid freeze-dried powder injection can be used for treating bleeding caused by acute and chronic, local or systemic primary fibrinolysis hyperfunction, bleeding caused by visceral trauma or operations, fibrinolytic bleeding, menorrhagia and other diseases.

Water-soluble artemisinin derivatives, their preparation methods, the pharmaceutical compositions containing the same derivatives and the use thereof are disclosed. The artemisinin derivatives have following formula I. It has been proved by pharmacological tests that these compounds and compositions have evident immuno-suppressive activities, and may be used in the preparation of novel immuno-suppressants for treating the diseases caused by hyperfunction of human immunity (e.g. the auto-immune diseases such as lupus erythematosus, rheumatoid arthritis, multiple sclerosis and the like), and for inhibiting the graft rejection after cell or organ transplantation.

The invention relates to a trichosanthin effective epitope peptide fragment with an immunosuppression effect and application of the trichosanthin effective epitope peptide fragment, and discloses a trichosanthin effective epitope peptide PA and a trichosanthin effective epitope peptide PAQ, wherein an amino acid sequence of the trichosanthin effective epitope peptide PA is as shown in SEQ ID NO: 1; an amino acid sequence of the trichosanthin effective epitope peptide PAQ is as shown in SEQ ID NO: 4. The trichosanthin effective epitope peptide fragment PA and PAQ obtain effects in the experiment research on treatment of allogeneic mixed lymphocyte proliferation of immune response hyperfunction and obtains effects in the research on treatment on latent autoimmune diabetes in adults. According to the invention, the conventional method is broken through; parts with toxic or side effects are removed from a trichosanthin molecular structure and effective biological activity parts of the trichosanthin molecular structure are kept; a novel low-toxicity high-efficiency preparation which really can be used for treating various clinical diseases is developed.

The invention provides the application of thymic peptide Beta4 in preparing drugs for preventing and curing bronchial asthma. The test shows that the thymic peptide Beta4 can increase the tidal volume, reduce the breathing frequency and improve the pulmonary ventilation function of a mouse; the thymic peptide Beta4 can inhibit the hyperfunction of a Th2 cell subgroup, reduce the generation of IL-5 and prevent eosinophile granulocyte from aggregating and adhering so as to alleviate the inflammation of an airway and lung tissue; the thymic peptide Beta4 adopts the ways to interfere the occurrence of asthma, alleviate the symptoms of the asthma, defer the irreversibility of airway obstruction and recover the lung function level of the asthma. The application of the invention provides a base for new drug screening.

The invention relates to a pharmaceutical composition for treating cancer and a preparing method thereof. The composition is prepared from 3.6-5.5 parts of coptidis rhizome, 7.2-9.9 parts of fructus forsythia, 3.6-5.5 parts of cortex phellodendri, 4.5-6.6 parts of licorice root, 6.3-8.8 parts of radix scutellariae, 7.2-11 parts of radix trichosanthis, 4.5-6.6 parts of fructus gardenia, 8.1-11 parts of radix scrophulariae, 4.5-6.6 parts of rhizoma anemarrhenae, 6.3-8.8 parts of radix rehmanniae preparata and 3.6-5.5 parts of radix platycodi. The preparing method comprises the steps of soaking the raw materials in honey for 5-10 h, and then conducting drying and smashing. The pharmaceutical composition can clear heat, purge intense heat, relieve internal heat or fever, promote blood circulation to remove blood stasis and eliminate lumps, it is proved through clinical verification that treatment effect is remarkable, cure rate is as high as 85%, and relapse rate is low. The pharmaceutical composition does not need to be decocted, is ready to eat, has a good taste, and can activate the detoxifying function of internal organs, inhibit hyperfunction of cancer cells, improve immunity and help patients regain health.

The invention discloses an ovarian function-related protein. The ovarian function-related protein is protein consisting of amino acid sequences shown by SEQ ID No.2 or derived protein with the same or similar activity and formed by substituting/or deleting and/or adding the amino acid sequences shown by the SEQ ID No.2 by one or more amino acid sequences. The invention further discloses an encoding gene of the protein, a recombinant expression carrier containing the gene, a transformant containing the recombinant expression carrier, and a preparation method of the protein and an antibody thereof. The ovarian function-related protein possibly takes part in cell signal transduction and mature regulation of ova, plays a certain effect during a fertilization process, and shows potential of being further developed into a novel diagnostic reagent or a preventive drug for diseases caused by hypofunction, deletion or hyperfunction of the protein.

The compound liniment for curing autoimmune disease is formed from matrix and effective component, said matrix comprises 15-25% of effective component which comprises artificial musk and levamisole, the mass ratio of both them is 1:1.2. The artificial musk possesses strong systemic property and strong action of relieving inflammation, and the levamisole is an immunodepressant, and can suppress immunological hyperfunction, so that said liniment possesses the obvious therapeutic effect for curing rheumatoid arthritis, lupus sebaceus and ankylosing spondylitis, etc.

The invention discloses a capsule preparation of the volatile oil of fenugreek and a quality control method thereof. The capsule preparation of the volatile oil of the fenugreek has anti-virus, anti-bacterial, anti-inflammatory, antidiarrheal, pain-relieving and antipyretic effects, and can inhibit gastrointestinal hyperfunction .

The invention discloses a palm-type rehabilitation brace. The palm-type rehabilitation brace comprises a brace body, a palm brace section of the brace body, a fixing section connected to the jaw part of the palm brace section and bent to the back of the hand, and also comprises a fixing mechanism used for mounting daily articles for carrying out the corresponding upper limb function operations, wherein the fixing mechanism is arranged on the surface of the inner palm part of the palm brace section, and comprises a plurality of velcro straps longitudinally and horizontally arranged, and the daily articles are fixed by adopting the longitudinal and horizontal velcro straps. The palm-type rehabilitation brace is suitable for being worn by patients without the obvious hyperfunction of the hand muscular tension or with low hyperfunction of hand muscular tension, is used for assisting the patients in carrying out some simple upper limb function operations, can arouse the interest of the patients in wearing the brace for a long term, and is also beneficial for the patients in using the residual wrist, elbow and shoulder functions of the upper limb, so that the rehabilitation effect is achieved.

The invention belongs to the pharmaceutical preparation field and relates to a pharmaceutical preparation which takes molecule p40 or a gene encoding molecule p40 as the active ingredient and is used for antagonism against immunoreaction caused by interleukin-23 (IL-23). In particular the invention takes soluble molecule p40 or a gene which can express and secrete molecule p40 as the active ingredient, antagonizes the immunoreaction which is mediated by IL-23 and unfavorable to organisms, can be widely applied to treat immunological diseases such as collagenosis, multiple sclerosis, rheumatoid arthritis, ulcerous colitis, I type diabetes mellitus, chronic thyroiditis and so on caused by such as immunoreaction abnormal hyperfunction, and also can be used to inhibit rejection reactions of the organisms to implants.